NASDAQ:ATXS Astria Therapeutics (ATXS) Stock Price, News & Analysis $12.44 +0.06 (+0.48%) Closing price 04:00 PM EasternExtended Trading$12.44 0.00 (0.00%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Astria Therapeutics Stock (NASDAQ:ATXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Astria Therapeutics alerts:Sign Up Key Stats Today's Range$12.43▼$12.5550-Day Range$6.18▼$12.4452-Week Range$3.56▼$12.55Volume812,055 shsAverage Volume4.03 million shsMarket Capitalization$702.11 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview Astria Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues. Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders. Its lead clinical programs are designed to harness bispecific constructs and cell‐based activation technologies to improve the precision and durability of immune killing, while additional preclinical assets focus on expanding the scope of treatable targets and refining safety profiles. Founded in 2018 and headquartered in San Diego, California, Astria Therapeutics collaborates with academic institutions, contract research organizations and regulatory authorities throughout North America and Europe to advance its product candidates. The company is guided by an executive team with extensive biopharmaceutical industry experience and a board of directors that brings together scientific, clinical and commercial expertise to support its strategic development plan.AI Generated. May Contain Errors. Read More Astria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreATXS MarketRank™: Astria Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 703rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingAstria Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 3 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialAstria Therapeutics has a consensus price target of $25.00, representing about 101.0% upside from its current price of $12.44.Amount of Analyst CoverageAstria Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Astria Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Astria Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.87% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Astria Therapeutics has recently increased by 5.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.87% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Astria Therapeutics has recently increased by 5.78%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment-0.47 News SentimentAstria Therapeutics has a news sentiment score of -0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Astria Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for ATXS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows4 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Astria Therapeutics' insider trading history. Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATXS Stock News HeadlinesAstria Therapeutics (ATXS) Gets a Buy from LifeSci CapitalOctober 20, 2025 | theglobeandmail.comBrokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $27.14October 20, 2025 | americanbankingnews.comThis dark force is about to change everythingAn unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.October 24 at 2:00 AM | Porter & Company (Ad)Astria Therapeutics (NASDAQ:ATXS) Cut to Hold at HC WainwrightOctober 19, 2025 | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Cut to "Hold" at Citizens JmpOctober 18, 2025 | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Cut to Neutral at WedbushOctober 18, 2025 | americanbankingnews.comAstria Therapeutics' (ATXS) Market Perform Rating Reiterated at JMP SecuritiesOctober 18, 2025 | americanbankingnews.comAstria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria ...October 17, 2025 | tmcnet.comSee More Headlines ATXS Stock Analysis - Frequently Asked Questions How have ATXS shares performed this year? Astria Therapeutics' stock was trading at $8.94 on January 1st, 2025. Since then, ATXS shares have increased by 39.1% and is now trading at $12.44. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) announced its earnings results on Tuesday, August, 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.04. When did Astria Therapeutics' stock split? Astria Therapeutics's stock reverse split on the morning of Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. Who are Astria Therapeutics' major shareholders? Top institutional investors of Astria Therapeutics include Voya Investment Management LLC (0.04%) and Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Perceptive Advisors Llc and Christopher Morabito. View institutional ownership trends. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Astria Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AUO (AUOTY). Company Calendar Last Earnings8/12/2025Today10/24/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATXS CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees30Year Founded2008Price Target and Rating Average Price Target for Astria Therapeutics$25.00 High Price Target$49.00 Low Price Target$13.00 Potential Upside/Downside+101.0%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$94.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.39% Return on Assets-36.08% Debt Debt-to-Equity RatioN/A Current Ratio14.89 Quick Ratio14.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book3.13Miscellaneous Outstanding Shares56,440,000Free Float53,895,000Market Cap$702.11 million OptionableOptionable Beta0.43 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ATXS) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.